Clinical trial

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

NCT06906081

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Kerendia (Finerenone, BAY94-8862) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-05-02

PhasePHASE2

Conditions

Cardiovascular Autonomic Neuropathyunresolved

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

Diabetic Neuropathiesunresolved

Interventions

Kerendia (Finerenone, BAY94-8862)DRUG

PlaceboDRUG

Sponsors & collaborators

Peter Rossinglead sponsor

Steno Diabetes Center Nordjyllandcollaborator

Aarhus University Hospitalcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06906081 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.